Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male between the ages of 18 and 35 years~2. Able and willing to be located easily by providing street address and telephone number (land line and/or cell phone number)~3. Able and willing to provide written informed consent~4. Able and willing to attend all study visits and follow-up visit during the week after treatment~5. Willing to abstain from masturbation during the 6 days after inoculation~6. Willing to abstain from all sexual activity during the course of the study~7. No clinically significant abnormalities on physical examination~8. No clinically significant abnormalities in serum chemistries, hematology and urinalysis~9. Urine negative for chlamydia, gonorrhea and trichomonas~10. No history of sexually transmitted infections (STIs), including syphilis and hepatitis B (HBV) \& hepatitis C (HCV)~11. Negative human immunodeficiency virus (HIV), syphilis and HCV serologies~12. Negative HBV core and surface antibodies or results consistent with immunization (negative HBV core antibody/positive HBV surface antibody)~13. No history of bleeding diathesis~14. No history of seizures (due to reports of seizures with ciprofloxacin)~15. No history of cancer, except basal cell carcinoma of the skin more than 5 years ago~16. No history of drug abuse~17. No history of psychiatric disorders, except depression controlled by medication~18. No history of genitourinary surgery~Exclusion Criteria:~1. Student or employee under the direct supervision of any of the study investigators~2. Any known immunodeficiencies including complement deficiency, antibody deficiency, chronic granulomatous disease or HIV infection~3. Sickle cell disease~4. Psychiatric disorders that would interfere with the ability of the subject to comply with the requirements of the protocol~5. Unstable depression (defined as receiving either \<3 months of the same medication (and dose) or a decompensating event during the previous 3 months) or depression that, in the opinion of the investigator, will compromise the subject's ability to comply with protocol requirements~6. Heart murmur or heart disease~7. Anatomic abnormality of the urinary tract~8. Any antibiotic treatment in the past 30 days, or azithromycin in the past 60 days~9. Chemotherapy within the past year~10. Current steroid use, except for topical application~11. Allergy to penicillin, cephalosporins, ciprofloxacin or to lidocaine~12. Treatment with medications that are contraindicated with cefixime, ceftriaxone or ciprofloxacin and that cannot be withheld for the single doses given in this study.~    1. Medications not permitted with cefixime or ceftriaxone include:~       * Warfarin~      * Probenecid~      * Aspirin~      * Diuretics such as furosemide~      * Aminoglycoside antibiotics~      * Chloramphenicol~   2. Medications not permitted with ciprofloxacin include:~       * Tizanidine~      * Theophylline~      * Warfarin~      * Glyburide~      * Cyclosporine~      * Probenecid~      * Phenytoin~      * Methotrexate~      * Antacids, multivitamins, and other dietary supplements containing magnesium, calcium, aluminum, iron or zinc~      * Caffeine-containing medications~      * Sucralfate or didanosine chewable or buffered~13. Major organ dysfunction~14. Any significant pre-existing condition preventing full compliance with the study~15. Infection or any serious underlying medical condition that would impair the ability of the subject to receive protocol treatment

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): Control subjects will not receive an infusion or placebo
- 1 mg/kg single infusion of F598 (Type: EXPERIMENTAL): 1 mg/kg single infusion of F598
- 3 mg/kg single infusion of F598 (Type: EXPERIMENTAL): 3 mg/kg single infusion of F598
- 10 mg/kg single infusion of F598 (Type: EXPERIMENTAL): 10 mg/kg single infusion of F598

Based on this trial design, predict the completion outcome and termination type (if applicable).